Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's revenue and growth potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the Class Period [2]. Group 2: Legal Process and Participation - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff, representing the class in the litigation [3]. - A lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Viewpoint - Investors in C3.ai, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's growth and the health of its CEO [1][2]. Summary by Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 8, 2025, C3.ai's management failed to disclose critical information, including that the company's optimistic growth reports were overly reliant on the CEO's health, which had not sufficiently improved [2]. - It is alleged that the positive statements made by the company regarding its business operations and future prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses on their C3.ai investments are encouraged to participate in the class action lawsuit, with a lead plaintiff deadline set for October 21, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating AVITA Medical, Inc. for potential violations of federal securities laws following significant financial issues related to unpaid claims for its Recell procedures [1][2]. Financial Performance - On August 7, 2025, AVITA Medical reported its second quarter 2025 financial results, indicating a six-month backlog in unpaid provider claims for Recell procedures, which negatively impacted first-half demand [2]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers and reduced utilization of Recell [2]. Stock Market Reaction - Following the announcement of the financial issues, AVITA's stock price dropped by $1.13, or 21%, closing at $4.25 per share on August 8, 2025, resulting in losses for investors [2].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating America's Car-Mart, Inc. for potential violations of federal securities laws following significant stock price declines related to financial disclosures and performance issues [1][2][3][4]. Group 1: Investigation Background - On July 15, 2025, Car-Mart announced a delay in filing its annual report due to the need for enhanced disclosures regarding loan modifications for financially distressed borrowers, resulting in a stock price drop of $3.12 (5.2%) to $57.26 [2]. - On July 30, 2025, Car-Mart revealed that certain previously issued financial statements were no longer reliable due to omissions in disclosures about loan modifications, causing the stock price to fall by $3.70 (7.5%) to $45.57 [3]. - On September 4, 2025, Car-Mart reported a 5.7% decline in sales volumes, attributing it to a focus on customer quality and vehicle performance, leading to a significant stock price drop of $8.14 (18.2%) to $36.51 [4].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were highly anticipated but yielded disappointing outcomes, raising concerns about the drug's regulatory approval and commercial viability [3]. Stock Market Impact - Following the announcement of the trial results, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Firefly Aerospace for possible violations of federal securities laws or other unlawful business practices [1][3]. Financial Performance - On August 7, 2025, Firefly offered 19,296,000 shares at a public offering price of $45.00 per share [3]. - Firefly reported revenue of $15.5 million for its initial quarterly results, reflecting a year-over-year decline of over 27% [3]. - The company reported total operating expenses of $58.3 million, which is a year-over-year increase of more than 12% [3]. - Following the financial report, Firefly's share price dropped by $7.58, or approximately 15.31%, from $49.52 on September 22, 2025, to close at $41.94 on September 23, 2025 [3].

LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 3, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tronox Holdings PLC (“Tronox” or the “Company”) (NYSE: TROX) common stock between February 12, 2025 and July 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR TRONOX INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS T ...

LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Dow Inc. (“Dow” or the “Company”) (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR DOW INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS U ...

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Informatica Inc., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][8]. Company Overview - Informatica develops an artificial intelligence-powered platform that connects, manages, and unifies data across multi-vendor, multi-cloud, and hybrid systems [3]. Financial Performance - On February 13, 2025, Informatica reported its fourth quarter of 2024 and fiscal 2024 financial results, missing financial projections. The company experienced a 3.8% year-over-year decrease in GAAP total revenues, a 2% year-over-year decrease in GAAP subscription revenues, and a 3.9% year-over-year decrease in non-GAAP operating income at the midpoint of the range. Following this announcement, Informatica's share price fell by more than 21% [4].

Core Points - The Gross Law Firm has issued a notice to shareholders of Fly-E Group, Inc. regarding a potential class action lawsuit due to misleading statements about the safety of its lithium batteries, which negatively impacted E-vehicle sales revenue [2][4] - The class period for the lawsuit is from July 15, 2025, to August 14, 2025, during which Fly-E allegedly provided overly positive statements while concealing material adverse facts [2][3] - On August 14, 2025, Fly-E reported a 32% decrease in net revenues, primarily due to a decline in total units sold, attributed to recent lithium-battery accidents [2][3] - Following the revelation, Fly-E's stock price plummeted from $7.76 per share to $1.00 per share, marking an approximate 87% decline in a single day [2][3] Company and Industry Summary - Fly-E Group, Inc. is facing legal challenges due to allegations of providing false and misleading information regarding the safety of its lithium batteries, which has led to significant financial losses for shareholders [2][4] - The company's revenue projections were significantly impacted as sales continued to decline while operating expenses increased, indicating potential mismanagement or over-optimism in forecasting [2][3] - The class action lawsuit aims to hold Fly-E accountable for the alleged deceitful practices that resulted in artificial inflation of its stock price prior to the disclosure of the adverse information [4]